Skip to main content
SpringerLink
Log in

Schmerztherapie von Skelettmetastasen mittels ionisierender Strahlung

  • Chapter
Praktische Schmerztherapie

  • 5 Accesses

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

Literatur zu Kap. 16.1

  • Adamietz IA, Diel IJ (2003) Bisphosphonate. Onkologe 9:495–509

    Article  Google Scholar 

  • Adamietz IA, Schneider O et al. (2002) Results of a nationwide survey on radiotherapy of bone metastases in Germany. Strahlenther Onkol 178,10:531–536

    Article  PubMed  Google Scholar 

  • Arcangeli G, Giovinazzo G et al. (1998) Radiation therapy in the management of symptomatic bone metastases: the effect of total dose and histology on pain relief and response duration. Int J Radiat Oncol Biol Phys 425:1119–1126

    Article  PubMed  CAS  Google Scholar 

  • Blitzer PH (1985) Reanalysis of the RTOG study of the palliation of symptomatic osseous metastasis. Cancer 55,7:1468–1472

    Article  PubMed  CAS  Google Scholar 

  • Bone-Trial-Working-Party (1999) 8 Gy single fraction radiotherapy for the treatment of metastatic skeletal pain: randomised comparison with a multifraction schedule over 12 months of patient follow-up. Bone Pain Trial Working Party. Radiother Oncol 52,2:111–121

    Google Scholar 

  • Böttcher HD, Adamietz IA (1997) Klinik der Skelettmetastasen. Zuck-schwerdt, München Bern Wien New York

    Google Scholar 

  • Hoskin PJ, Price P et al. (1992) A prospective randomised trial of 4 Gy or 8 Gy single doses in the treatment of metastatic bone pain. Radiother Oncol 23,2: 74–78

    Article  PubMed  CAS  Google Scholar 

  • Kagan AR, Rose CM et al. (2000) Bone metastases. American College of Radiology. ACR Appropriateness Criteria. Radiology 215Suppl: 1077–10104

    PubMed  Google Scholar 

  • Koswig S, Buchali A et al. (1999) Palliative Strahlentherapie von Knochenmetastasen. Eine retrospektive Analyse von 176 Patienten. Strahlenther Onkol 175,10:509–14

    Article  PubMed  CAS  Google Scholar 

  • Koswig S, Budach V (1999) Remineralisation und Schmerzlinderung von Knochenmetastasen nach unterschiedlich fraktionierter Strahlentherapie (10mal 3 Gy vs. 1mal 8 Gy). Strahlenther Onkol 175: 500–508

    Article  PubMed  CAS  Google Scholar 

  • Ratanatharathorn V, Powers WE et al. (1999) Bone metastasis: review and critical analysis of random allocation trials of local field treatment. Int J Radiat Oncol Biol Phys 441:1–18

    Article  PubMed  CAS  Google Scholar 

  • Rieden K, Adolph J et al. (1989) Strahlentherapeutischer Effekt bei knochenmetastasen in Abhängigkeit von der Metastasenhäufig, Metastasenlokalisation und der Histologie des Primärtumors. Strahlenther Onkol 165,5:380–385

    PubMed  CAS  Google Scholar 

  • Rieden K, Mende U et al. (1989) Akzelerierte Bestrahlung von Knochenmetastasen. Strahlenther Onkol 165,1:23–27

    PubMed  CAS  Google Scholar 

  • Salazar OM, DaMotta NW et al. (1996) Fractionated half-body irradiation for pain palliation in widely metastatic cancers: comparison with single dose. Int J Radiat Oncol Biol Phys 36,1:49–60

    Article  PubMed  CAS  Google Scholar 

  • Salazar OM, Sandhu T et al. (2001) Fractionated half-body irradiation HBI) for the rapid palliation of widespread, symptomatic, metastatic bone disease: a randomized Phase III trial of the International Atomic Energy Agency IAEA). Int J Radiat Oncol Biol Phys 50,3: 765–775

    Article  PubMed  CAS  Google Scholar 

  • Tong D, Gillick L et al. (1982) The palliation of symptomatic osseous metastases: final results of the Study by the Radiation Therapy Oncology Group. Cancer 50,5:893–899

    Article  PubMed  CAS  Google Scholar 

Literatur zu Kap. 16.2

  1. Atkins HL, Mausner LF Srivastava SC, Meinken GE et al. (1995) Tin-117m(4+)-DTPA for palliation of pain from osseous metstases: a pilotstudy. J Nucl Med 36: 725–729

    PubMed  CAS  Google Scholar 

  2. Averbuch SD (1993) New bisphosphonates in the treatment of bone metastases. Cancer Suppl 72:3443–3451

    CAS  Google Scholar 

  3. Baziotis N, Yakoumakis E, Zissimopoulos et al. (1998) Strontium-89 chloride in the treatment of bone metatases from breast cancer. Oncology 55:377–381

    Article  PubMed  CAS  Google Scholar 

  4. Blake GM, Zivanovic MA, McEwan AJB, Ackery DM (1986) Sr-89 therapy: strontium kinetics in disseminated carcinoma of the prostate. Eur J Nucl Med 12:447–454

    PubMed  CAS  Google Scholar 

  5. Bolger JJ, Dearnaley DP, Kirk D, Lewington VJ et al. (1993) Strontium-89 (Metastron) versus external beam radiotherapy in patients with painful bone metatases secondary to prostate cancer: preliminary report of a multicente trial. Sem Oncol 20,Suppl 2:32–33

    CAS  Google Scholar 

  6. Bouchet LG, Bolch WE, Goddu SM et al. (2000) Considerations in the selection of radiopharmaceuticals for palliation of bone pain from metastatic osseous lesions. J Nucl Med 41:682–687

    PubMed  CAS  Google Scholar 

  7. Brenner W, Kampen WU, Kampen AM, Henze E (2001) Skeletal uptake and soft tissue retention of 186-Re-HEDP and 153-Sm-EDTMP in patients with metastatic bone disease. J Nucl Med 42:231–236

    Google Scholar 

  8. Brucer M (1990) A chronology of nuclear medicine. Heritage Publications, St. Louis

    Google Scholar 

  9. Coleman RE (1997) Skeletal complications of malignancy. Cancer 80: 1588–1594

    Article  PubMed  CAS  Google Scholar 

  10. Coleman RE, Smith P, Rubens RD (1998) Clinical course and prognostic factors following bone recurrence from breast cancer. Br J Cancer 77:336–340

    PubMed  CAS  Google Scholar 

  11. Deguchi T, Yang M, Ehara H et al. (1997). Detection of micrometastatic prostate cancer cells in the bone marrow of patients with prostate cancer. Br J Cancer 75:634–638

    PubMed  CAS  Google Scholar 

  12. deKlerk JMH (1995) Re-186-HEDP in treatment of metatatic bone disease: pharmakokinetics and toxocity. Ponson & Looigen, Wagenningen

    Google Scholar 

  13. Ducy P, Schinke T, Karsenty G (2000) The osteoblast: a sophisticated fibroblast under central surveillance. Science 289:1501–1504

    Article  PubMed  CAS  Google Scholar 

  14. Elgazzar AH, Maxon HR (1993) Radioisotope therapy of cancer related bone pain. In: Limouris GS, Shukla SK (eds) Radionuclides for therapy. Mediterra, Athen, pp 111–116

    Google Scholar 

  15. Fischer M (1999) Leitlinie für die Radionuklidtherapie bei schmerzhaften Knochenmetastasen. Nuklearmedizin 38:270–272

    PubMed  CAS  Google Scholar 

  16. Fischer M, Böhme K (1996) Nuklearmedizinsche Schmerztherapie bei metastasiertem Prostatakarzinom. Nuklearmediziner 5:339–344

    Google Scholar 

  17. Fuster D, Herranz R, Vidal-Sicart S et al. (2000) Usefulness of strontium-89 for bone pain palliation in metastatic breast cancer patients. Nucl Med Commun 21:623–626

    Article  PubMed  CAS  Google Scholar 

  18. Galasko CSB (1982) Mechanisms of lytic and blastic metastatic disease of bone. Clin Orthop 169:20–27

    PubMed  Google Scholar 

  19. Geldof AA, de Rooij L, Versteegh RT et al. (1999) Combination 186-Re-HEDP and cisplatin supraadditive treatment effects in prostate cancer cells. J Nucl Med 40:667–671

    PubMed  CAS  Google Scholar 

  20. Goddu SM, Bbishayee A, Bouchet LG et al. (2000) Marrow toxicity of 33-P versus 32-P-orthophosphate: implication for therapy of bone pain and bone metastases. J Nucl Med 41:941–951

    PubMed  CAS  Google Scholar 

  21. Henriksen G, Breistøl K, Bruland ØS, Fodstad Ø, Larsen RH (2002) Significant antitumor effect from bone-seeking, α-particle-emitting 223-Ra demonstrated in an experimental skeletal metastases model. Cancer Res 62:3120–3125

    PubMed  CAS  Google Scholar 

  22. Kalesnikov-Gauthier H, Carpenier P, Depreux P et al. (2000) Evaluation of toxicity and efficacy of 186-Re-hydroxyethylidene diphosphonate in patients with painful bone metastases of prostate or breast cancer. J Nucl Med 41:1689–1694

    Google Scholar 

  23. Kasalický J, Kraská V (1998) The effect of repeated strontium-89 chloride therapy in bone pain palliation in patients with skeletal cancer metastases. Eur J Nucl Med 25:1362–1367

    Article  PubMed  Google Scholar 

  24. Krasnow AZ, Hellman RS, Timins ME, Collier BD, Anderson T, Isitman AT (1997) Diagnostic bone scanning in oncology. Semin Nucl Med 27:107–141

    Article  PubMed  CAS  Google Scholar 

  25. Krishnamurthy GT, Krishnamurthy S (2000) Invited commentary: Radionuclides for metastatic bone pain palliation: a need for rational re-evaluation in the new millenium. J Nucl Med 41:688–691

    PubMed  CAS  Google Scholar 

  26. Lau WF, Hicks R, Binns D (2001) Differential effects of bisphosphonate on Paget’s disease and metastatic prostatic carcinoma bone scan findings. Clin Nucl Med 26:347–348

    Article  PubMed  CAS  Google Scholar 

  27. Liepe K, Franke W-G, Koch R et al. (2000) Comparison of Rhenium-188, Rhenium-186 and Strontium in palliation of painful bone metastases. Nuklearmedizin 39:146–151

    PubMed  CAS  Google Scholar 

  28. Malmberg I, Persson U, Ask A et al. (1997) Painful bone metastases in hormon-refractory prostate cancer: economic cost of strontium-89 and/or external radiotherapy. Urology 50: 747–753

    Article  PubMed  CAS  Google Scholar 

  29. Marcus CS, Saeed S, Mlikotic A, Mishkin F, Pham HL, Javellana T, Diestelhorst S, Minami C (2002) Lack of effect of a bisphosphonate (pamidronate disodium) infusion on subsequent skeletal uptake of Sm-153-EDTMP. Clin Nucl Med 27:427–430

    Article  PubMed  Google Scholar 

  30. Maxon HR, Deutsch EA, Thomas SR, Libson K (1988) Re-186 (Sn) HEDP for treatment of multiple metastatic foci in bone: human biodistribution and dosimetric studies. Radiology 166:501–507

    PubMed  CAS  Google Scholar 

  31. McCready VR, O’Sullivan J, Dearnaly D, Cook G (2002) Prediction of response of skeletal metastases from cancer of the prostate to high activity 186-Re HEDP therapy. J Nucl Med 43Suppl 316 (abstr.)

    Google Scholar 

  32. McEwan AJB (1994) Palliation of bone pain. In: Murray IPC, Ell PJ (Hrsg) Nuclear medicine in clinical diagnosis and treatment. Churchill Livingston, Edinburgh, pp 877–892

    Google Scholar 

  33. McEwan AJB et al. (1994) A retrospective analysis of the cost effectiveness of treatment with Metastron in patients with prostate cancer metastatic to bone. Eur J Urol 26,Suppl 1:26–31

    Google Scholar 

  34. Nilsson S, Larsen RH, Fossa SD et al. (2005). First clinical experience with alpha-emitting radium-223 in the treatment of skeletal metastases. Clin Cancer Res 11:4451–4459

    Article  PubMed  CAS  Google Scholar 

  35. Palmedo H, Manka-Waluch A, Albers P et al. (2003). Repeated bontargeted therapy for hormone-refractory prostate carcinoma: randomized phase II trial with the new, high-energy radiopharmaceutical rhenium-188 hydroxyethylidenediphosphonate. J Clin Oncol 21: 2869–2875

    Article  PubMed  CAS  Google Scholar 

  36. Paulus P (1995) Re-186-HEDP in routine use: correlation between dose rate measurements and clinical efficacy. Update 1:17–20

    Google Scholar 

  37. Pecher C (1942) Biological investigations with radioactive calcium and strontium: preliminary report on the use of radioactive strontium in the treatment of metastatic bone cancer. Univ California Publ Pharmacol 2:117–149

    CAS  Google Scholar 

  38. Pons F, Herranz R, Garcia A, Vidal-Sicart S, Conill C, Grau JJ, Alcover J, Fuster D, Setoain J (1997) Strontium-89 for palliation of pain from bone metastases in patients with prostate and breast cancer. Eur J Nucl Med 24:1210–1214

    Article  PubMed  CAS  Google Scholar 

  39. Porter AT, McEwan AJB, Powe JE, Reid R et al. (1993) Results of a randomized phase-III trial to evaluate the efficacy of strontium-89 adjuvant to local external beam irradiation in the managemant of endocrine resistant metastatic prostate cancer. Int J Rad Oncol Biol Phys 25:805–813

    CAS  Google Scholar 

  40. Roodman GD (1997) Mechanisms of bone lesions in multiple myeloma and lymphoma. Cancer 80:1557–1514

    Article  PubMed  CAS  Google Scholar 

  41. Sciuto R, Tofani A, Festa A et al. (2000) Short-and long-term effects of 186-Re-1,-hydroxyethylidene diphosphonate in the treatment of painful bone metastases. J Nucl Med 41:647–654

    PubMed  CAS  Google Scholar 

  42. Sciuto R, Festa A, Rea S et al. (2002) Effects of low-dose Cisplatin on 89-Sr therapy for painful bone metastases from prostate cancer: a randomized clinical trial. J Nucl Med 43: 79–86

    PubMed  CAS  Google Scholar 

  43. Serafini AN (2000) Samarium Sm-153 Lexidronam for the palliation of bone pain associated with metastases. Cancer 88(Suppl) 2034–2039

    Google Scholar 

  44. Serafini AN (2001) Therapy of metstatic bone pain. J Nucl Med 42: 895–906

    PubMed  CAS  Google Scholar 

  45. Singh A, Holmes RA, Farhangi M, Volkert WA (1989) Human pharmacokinetics of Samarium-153 EDTMP in metastatic cancer. J Nucl Med 30:1814–1818

    PubMed  CAS  Google Scholar 

  46. Soerdjbalie-Maikoe V, Pelger RCM, Lycklama á Nijeholt GAB et al. (2002) Strontium-89 (Metastron) and the bisphosphonate olpadronate reduce the incidence of spinal cord compression in patients with hormone-refractory prostate cancer metastatic to the skeleton. Eur J Nucl Med 29:494–498

    Article  CAS  Google Scholar 

  47. Tannock I, Gospodarowicz M, Meakin W, Panzarella T, Stewart L, Rider W (1989) Treatment of metastatic cancer with low-dose prednisone: evaluation of pain and quality of life as pragmatic indices of response. J Clin Oncol 7:590–597

    PubMed  CAS  Google Scholar 

  48. Tu SM, Delpass ES, Jones D et al. (1997) Strontium-89 combined with doxorubicin in the treatment of patients with androgen independent prostate cancer. Urol Oncol 2:191–197

    Google Scholar 

  49. Tu SM, Millikan RE, Mengistu B et al. (2001). Bone-targeted therapy for advanced androgen-independent carcinoma of the prostate: a randomised phase II trial. Lancet 357:336–341

    Article  PubMed  CAS  Google Scholar 

  50. Wagner G (1984) Frequency of pain in patients with cancer. Recent Results Cancer Res 89:64–71

    PubMed  CAS  Google Scholar 

  51. World Health Organisation (1990) Cancer pain relief and palliative care. WHO Tech Rep Ser 804:7–73

    Google Scholar 

  52. Zyskowski A, Lamb D, Morum P et al. (2001) Strontium-89 treatment for prostate cancer bone metastases: does a protate specific antigen response predict for improved survival? Aust Radiol 45:39–42

    Article  CAS  Google Scholar 

Download references

Editor information

Editors and Affiliations

  1. Sektion Neurologische Schmerzforschung und -therapie Klinik für Neurologie, Universitätsklinikum Schleswig-Holstein, Campus Kiel, Schittenhelmstraße 10, 24105, Kiel

    Ralf Baron

  2. Klinik für Anästhesie, Intensivmedizin und Schmerztherapie, Rotes Kreuz Krankenhaus, St.-Pauli-Deich 24, 28199, Bremen

    Michael Strumpf

Rights and permissions

Reprints and permissions

Copyright information

© 2007 Springer Medizin Verlag Heidelberg

About this chapter

Cite this chapter

(2007). Schmerztherapie von Skelettmetastasen mittels ionisierender Strahlung. In: Baron, R., Strumpf, M. (eds) Praktische Schmerztherapie. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-540-49663-2_16

Download citation

  • DOI: https://doi.org/10.1007/978-3-540-49663-2_16

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-540-23091-5

  • Online ISBN: 978-3-540-49663-2

  • eBook Packages: Medicine (German Language)

Publish with us

Policies and ethics

Search

Navigation